<a href="https://www.fiercebiotech.com/biotech/kardigan-itching-ipo-fund-late-stage-cardiovascular-pipeline" hreflang="en">Kardigan itching for IPO to fund late-stage cardiovascular pipeline </a>
Kardigan, a Bay Area biotech focused on cardiovascular treatments, is planning an IPO to fund the development of its late-stage pipeline, which includes drugs like danicamtiv for genetic dilated cardiomyopathy and ataciguat for calcific aortic valve stenosis. Led by veterans from MyoKardia, the company aims to emulate successful drug development in cardiovascular disease, following a strong initial funding of $300 million and $254 million in previous rounds.
Kardigan, a cardiovascular-focused biotech, is planning an IPO to fund its late-stage pipeline, which includes danicamtiv for genetic dilated cardiomyopathy and ataciguat for calcific aortic valve stenosis. With a leadership team that successfully sold MyoKardia to Bristol Myers Squibb for $13.1 billion, Kardigan's IPO could be a strategic move for investors interested in capitalizing on promising cardiovascular drug developments.